Genetic Polymorphisms Associated with Adverse Reactions of Molecular-targeted Therapies in Renal Cell Carcinoma

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2018 Jan 6

PMID 29302760

Citations 6

Authors

Kazuhiro Yamamoto

Ikuko Yano

Affiliations

Soon will be listed here.

Abstract

The prognosis of patients with metastatic renal cell carcinoma has drastically improved due to the development of molecular-targeted drugs and their use in clinical practice. However, these drugs cause some diverse adverse reactions in patients and sometimes affect clinical outcomes of cancer therapy. Therefore, predictive markers are necessary to avoid severe adverse reactions, to establish novel and effective prevention methods, and to improve treatment outcomes. Some genetic factors involved in these adverse reactions have been reported; however, perspectives on each adverse response have not been integrated yet. In this review, genetic polymorphisms relating to molecular-targeted therapy-induced adverse reactions in patients with renal cell carcinoma are summarized in the points of pharmacokinetic and pharmacodynamic mechanisms. We also discuss about the relationship between systemic drug exposure and adverse drug reactions.

Citing Articles

Du R, Wang X, Zhou H, Ma L, Larcher L, Chen C Support Care Cancer. 2022; 30(12):9889-9899.

PMID: 36400979 DOI: 10.1007/s00520-022-07451-2.

Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study.

Du R, Yang H, Zhu J, Zhou H, Ma L, Getu M Asia Pac J Oncol Nurs. 2022; 9(10):100115.

PMID: 36118625 PMC: 9479359. DOI: 10.1016/j.apjon.2022.100115.

The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.

Du R, Yang H, Zhou H, Ma L, Getu M, Chen C BMC Cancer. 2022; 22(1):491.

PMID: 35505288 PMC: 9066960. DOI: 10.1186/s12885-022-09599-w.

Suspected Adverse Drug Reactions in Pediatric Cancer Patients in China: An Analysis of Henan Province Spontaneous Reporting System Database.

Jiao Z, Feng Z, Yan Z, Zhang J, Li G, Wang G Front Oncol. 2022; 11:807171.

PMID: 34988029 PMC: 8721046. DOI: 10.3389/fonc.2021.807171.

Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China.

Du R, Wang X, Ma L, Larcher L, Tang H, Zhou H BMC Cancer. 2021; 21(1):206.

PMID: 33639888 PMC: 7916285. DOI: 10.1186/s12885-021-07946-x.

References

Josephs D, Fisher D, Spicer J, Flanagan R . Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit. 2013; 35(5):562-87. DOI: 10.1097/FTD.0b013e318292b931. View

Houk B, Bello C, Poland B, Rosen L, Demetri G, Motzer R . Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2009; 66(2):357-71. DOI: 10.1007/s00280-009-1170-y. View

Chu Y, Li H, Tan H, Koh V, Lai J, Phyo W . Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One. 2015; 10(8):e0134102. PMC: 4526634. DOI: 10.1371/journal.pone.0134102. View

Tirona R, Lee W, Leake B, Lan L, Cline C, Lamba V . The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med. 2003; 9(2):220-4. DOI: 10.1038/nm815. View

Vaziri S, Kim J, Ganapathi M, Ganapathi R . Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep. 2010; 12(2):102-8. DOI: 10.1007/s11912-010-0085-4. View

Diekstra M, Swen J, Boven E, Castellano D, Gelderblom H, Mathijssen R . CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015; 68(4):621-9. DOI: 10.1016/j.eururo.2015.04.018. View

Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens F . Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics. 2016; 17(14):1483-90. DOI: 10.2217/pgs-2016-0063. View

Hacking D, Knight J, Rockett K, Brown H, Frampton J, Kwiatkowski D . Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. Genes Immun. 2004; 5(4):274-82. DOI: 10.1038/sj.gene.6364067. View

Bartnicka L, Kurzawski M, Drozdzik A, Plonska-Gosciniak E, Gornik W, Drozdzik M . Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacol Rep. 2007; 59(3):323-9. View

10.

Kim H, Park H, Kwon W, Lee J, Tanigawara Y, Lim S . Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013; 72(4):825-35. DOI: 10.1007/s00280-013-2258-y. View

11.

Xu C, Reck B, Goodman V, Xue Z, Huang L, Barnes M . Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2010; 54(6):1237-43. DOI: 10.1016/j.jhep.2010.09.028. View

12.

de Velasco G, Gray K, Hamieh L, Urun Y, Carol H, Fay A . Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2017; 2(6):633-639. PMC: 5520643. DOI: 10.1016/j.euf.2016.03.017. View

13.

Olynyk J, Knuiman M, Divitini M, Bartholomew H, Cullen D, Powell L . Effects of HFE gene mutations and alcohol on iron status, liver biochemistry and morbidity. J Gastroenterol Hepatol. 2005; 20(9):1435-41. DOI: 10.1111/j.1440-1746.2005.03967.x. View

14.

Choi H, Bae K, Cho S, Ghim J, Choe S, Jung J . Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Pharmacogenet Genomics. 2015; 25(12):595-608. DOI: 10.1097/FPC.0000000000000176. View

15.

Lee S, Bang Y, Mainwaring P, Ng C, Chang J, Kwong P . Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clin Oncol. 2014; 10(3):237-45. DOI: 10.1111/ajco.12163. View

16.

Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K . Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2015; 13(4):350-358. DOI: 10.1016/j.clgc.2015.01.007. View

17.

Xu C, Johnson T, Wang X, Carpenter C, Graves A, Warren L . HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clin Cancer Res. 2015; 22(6):1371-7. PMC: 7444994. DOI: 10.1158/1078-0432.CCR-15-2044. View

18.

Xu C, Johnson T, Garcia-Donas J, Choueiri T, Sternberg C, Davis I . IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br J Cancer. 2015; 112(7):1190-8. PMC: 4385958. DOI: 10.1038/bjc.2015.64. View

19.

Crofts F, Taioli E, Trachman J, Cosma G, Currie D, Toniolo P . Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 1994; 15(12):2961-3. DOI: 10.1093/carcin/15.12.2961. View

20.

Low S, Fukunaga K, Takahashi A, Matsuda K, Hongo F, Nakanishi H . Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction. PLoS One. 2016; 11(2):e0148177. PMC: 4767438. DOI: 10.1371/journal.pone.0148177. View